Category Health Policy Watch

Innovations For All: Swiss-Led Panel Looks At What Works, What Doesn’t

The current innovation system has yielded many important innovations and extended human life, nobody disputes this. But what about the cases where it hasn’t and a problem persists? A panel of health experts organised recently by the Swiss government and including representatives of the pharmaceutical industry, the World Health Organization, academia, and a research institution held an unusually open and positive discussion that sought to get underneath the issue.

Do We Need A Global Body To Set Priorities For Diseases And Research?

A recent panel of health experts gathered at the hallowed Swiss Intellectual Property Institute in Bern (which counts Albert Einstein among its alumni) tackled some of the toughest questions facing global health policymakers with an eye toward actually solving them and not just restating polarised positions. One of the ideas discussed at the event was how priorities for diseases and research are handled at the global level.

Trump Budget Would Slash Funding For Health, International Organisations

The Trump administration this week proposed drastic cuts in funding for international activities including foreign policy and global health in 2019, while further building up military and big business activities. Programs related to international activities will have to prove their value to American interests and other countries are demanded to pay more, according to the proposed budget sent yesterday to Congress, which is ultimately expected to set about the task of restoring numerous programs.

Leadership And Change: An Interview With Medicines Patent Pool Board Chair Marie-Paule Kieny

The unexpected announcement in December of the resignation of the Medicines Patent Pool executive director left the Pool searching for its new head. Marie-Paule Kieny, former World Health Organization assistant director general, now chair of the MPP governance board stepped in to oversee the MPP while the search goes on. She sat down recently for an interview with Intellectual Property Watch to explain that MPP is conducting business as usual, and is keeping firm in its plan to release the results of a feasibility study analysing the possibility for MPP to extend its licensing activities to other essential medicines still under patent.

WHO To Help Countries With Price Transparency, Regulation, TRIPS Flexibilities

World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference yesterday to present progress made since his election last May. His office answered a follow-up question today from Intellectual Property Watch on access to medicines and how the organisation could help countries to do a better job.

WHO Director Presents The Press With Progress Report, Answers Tough Questions

Following a promise made at the beginning of his tenure to meet with the press regularly, World Health Organization Director General Tedros Adhanom Ghebreyesus (Dr Tedros) held a press conference today to paint a picture of what has been done under his leadership for the last seven months. He highlighted the establishment of the WHO General Programme of Work for 2019-2023, the quest for a new resource mobilisation strategy, measures taken on emergencies, and the push for universal health coverage. He also answered questions about the WHO nomination of President Mugabe that was cut short, and an appointment in his leadership team.

New Open Source Drug Discovery Initiative Takes Aim At “Devastating” Disease

A consortium including the Drugs for Neglected Disease initiative has launched a groundbreaking open source drug discovery project as way to find new drugs to treat mycetoma, a "devastating disease for which current treatments are ineffective, expensive, and toxic," the group said.

Leaked Letter Shows Pressure On Colombia Not To Issue Compulsory Licence For Glivec

A newly leaked 2016 letter from the CEO of Novartis to the president of Colombia, made available by Swiss group Public Eye, shows the level of concern the Swiss pharmaceutical company had over the effect of possible issuance of a compulsory licence for Novartis drug Glivec in the pivotal South American economy.

Medicines Innovation And Access: Swiss Stimulate New Thinking

BERN, Switzerland -- What if reaching the United Nations Sustainable Development Goals on access to health for all depended on the willingness of all actors to see beyond outdated dichotomies? The concept may seem obvious, but is easier described than done. In an effort to break silos, the Swiss Federal Institute of Intellectual Property (IPI) brought together stakeholders of all sides last week to discuss how to harness political and economic will to achieve innovation leading to new medicines that are available and affordable for all in need.